KR20050055096A - Phamaceutical composition comprising poria cocas wolf, cyperus rotundu, pinellia ternata tenore et breit, citrus nobilis, euphoria longana, nymphaea nelumbo l., aucklandia lappa dene, gardenia jasminoides for. grandiflora as main ingredients - Google Patents

Abstract

The present invention is present in the water extract (Poria cocas Wolf), Cyperus rotundu, Pinja (Pinellia ternata Tenore et Breit.), Dermis (Citrus nobilis), Euphoria longana, Nyphaea nelumbo L. A pharmaceutical composition consisting of extracts from powders of Aucklandia lappa Dene, Gardenia jasminoides for grandiflora, or water selected from them.The composition is composed of cardiovascular diseases such as hypertension, hypertension, stroke, and myocardial infarction. It has a pharmaceutical composition that is excellent for the treatment of symptoms caused by angina and thrombus.

Description

Pakaceutical composition comprising Poria cocas Wolf, Cyperus rotundu, Pinellia ternata Tenore et Breit, Citrus nobilis, Euphoria longana, Nymphaea nelumbo L., Aucklandia lappa Dene, Gardenia jasminoides for. grandiflora as main ingredients}

The present invention includes Poria cocas Wolf, Cyperus rotundu, Pinellia ternata Tenore et Breit., Dermis (Citrus nobilis), Euphoria longana, Nyphaea nelumbo L., Auklandia lappa Dene) and gardenia (Gardenia jasminoides for.grandiflora) as the main component of the cardiovascular diseases such as hypertension, hyperlipidemia, stroke, myocardial infarction, angina pectoris and cardiovascular diseases such as angina and excellent medicinal composition for the treatment of symptoms caused by blood clots It relates to pharmaceutical efficacy.

It is known that the number of senior workers in their 30s and 40s, who are national workers, complain of sudden or severe cardiovascular disease due to heavy work. Symptoms such as hypertension, hyperlipidemia, angina pectoris, stroke and myocardial infarction are caused by meat intake, excessive smoking, cholesterol and blood clots, and are also caused by genetic factors. Excessive work stress is a major factor in modern workplaces. Not only does it cause a lot of problems, but also a lot of medical burdens, the development of new materials that can be used in the overall clinical field is urgently required.

Cardiovascular diseases such as hypertension, hyperlipidemia, stroke, myocardial infarction, and angina pectoris are modern medical technologies, and the healing rate is improved by blood clots. However, these diseases are associated with cholesterol, NO, blood clots and myocardial tissue. Many biochemical changes in cells are caused by red defects, most of which are associated with mitochondrial dysfunction, accumulation of oxygen free or lipid peroxidation, inhibition of nucleic acid synthesis, and changes in electrolyte balance. In addition, there have been reports of causing heart failure and cardiac infarction in animals, and active researches on the approach of treatment methods including the mechanism of the pathogenesis of diseases related to cardiomyocyte necrosis are ongoing. The pharmaceutical market of cardiovascular therapeutics has helped lead the anti-hyperlipidemic drugs of statin drugs and angiotensin II inhibitors in the 1990s. Because instead. Business Communications reports that cardiovascular drugs include adrenergic inhibitors, adrenergic stimulators, angiotensin converting enzyme inhibitors (ACE inhibitors), angiotensin II inhibitors, beta blockers, calcium channels Calcium channel blockers, antithrombics, diuretics, steroids and steroidal glycosides, vasodilators, vasopressors, and other drugs are being produced. Reported. Millenium Pharmaceuticals, Inc., on the other hand, is a bioactive substance related to cardiovascular diseases such as atherosclerosis, hypertension, restenosis, and arterial inflammation, including vascular endothelial growth factor and angiopoietin-1. 1), fibroblast growth factors (fibroblast growth factors), gene discovery, recombination and protein production for the material is being developed as a treatment for the treatment of ischemic diseases and seems to be useful in the pharmaceutical industry. Patents related to such angiogenesis factors include (PCT: US 1995/05659, PCT: AU 1996/000094, PCT: US1997 / 15471, KR10-1999-0005259, and Korean Patent 10-2000-0053812). . When the blood supply to the heart is impaired, the cells respond by producing compounds that induce the growth of new blood vessels to increase the blood supply to the heart. One includes activation of genes encoding Vascular Endothelial Growth Factor (VEGF). For example, US Pat. No. 5,194,596 to Tisher et al. (Domestic Patent Application 1999-0005259) relates to the production of a novel angiopoietin-5 gene and recombinant angiogenic proteins using the same. A novel angiopoietin-5 gene sequence and amino acid sequence were isolated and identified from a cardiac cDNA library, and inserted into a mammalian expression vector. In the case of -0009097 (March 17, 1998; Rural Development Administration of Korea), a casein protein derived from human is synthesized a gene of peptide having inhibitory activity to increase blood pressure, and also to increase its expression in plants and stabilize expression products Isolate the ubiquitin gene of tomato and bind it to the peptide for inhibiting blood pressure rise, Experimental studies on cardiovascular and manufacturing of combined plant transgenic carriers reported that Ginseng reported blood pressure lowering effect and increased heart rate in ginseng. Han et al. Stimulated vascular endothelial cells to stimulate NO synthase activity. It was reported that the ginseng extract reported that the ginseng extract had a relaxing effect on vascular smooth muscle. On the other hand, Han et al reported a study on the protective effect of silicic acid on activator activity in cardiomyocytes, and Huh et al. On NO production in aortic smooth muscle in saline malic acid.

The present inventors have conducted a long study on herbal preparations that can be used for symptoms of cardiovascular diseases and blood clots such as hypertension, hyperlipidemia, stroke, myocardial infarction and angina pectoris. As a result, Poria cocas Wolf, Cyperus rotundu, Pinellia ternata Tenore et Breit., Dermis (Citrus nobilis), Euphoria longana, Nyphaea nelumbo L., Auklandia lappa Dene ), X-molecules extracted from powders of pharmaceutical compositions for treating cardiovascular diseases and blood clots, including hypertension, hyperlipidemia, stroke, myocardial infarction, and angina pectoris, containing gardenia jasminoides for grandiflora In the biological experiments, the present inventors have found surprising facts that suppress symptoms of cardiovascular diseases and blood clots such as hypertension, hyperlipidemia, stroke, myocardial infarction and angina.

Baekbokyeong (Poria cocas Wolf), which is the drug contained in the present invention, is parasitic on the root of red pine and reddish green is parasitic on the root of Gomsol. And what surrounds the pine root is called blessed. Taste is sweet and boring, and the nature of the flat (보) has a working effect and diuretic, but not strong. It has been used as a tonic since ancient times. It works on menopause, parenteral, heart, nerve, and bladder to protect the spleen, sputum, and stabilize the mind. The results of pharmacological experiments have been shown to act as a diuretic, lowering blood sugar, sedation, etc., and is also known as an immune resurrection.

Cyperus rotundu has red flowers in July-August and flowers in two rows and ripens in October. In oriental medicine, the tuber is used for pain relief, pain relief, cold, landscaping, health, gust, hari, sea, neuralgia, pulmonary tuberculosis, women's diseases, etc. The main ingredients are essential oils such as Cyperene and Cyperol. This medicine has been mentioned as a predecessor of gynecological diseases in Korea. It is effective for menstrual irregularities, postpartum headache, pain, pain, blood pressure, nerve stabilization, physical weakness, chronic gastrointestinal dysfunction, nervous dyspepsia, and loss of appetite. Has been recognized.

Pinellia ternata Tenore et Breit. Refers to rhizome (根 夏). Ingredients include homogentisic acid, β-sitosterol-3-o-β-D-glucoside, choline, ephedrine, arabiana and dihydroxybenzaldehyde. It is used in the anti, gastric constant, Jihaegu (구), stems and leaves are external to the force. As a folk medicine, half marinated in ginger juice was used for pregnancy vomiting and vomiting.

The dermis (Citrus nobilis) is mild, hot and sour, and the dermis is dried tangerine peel and the dermis or tangerine is dried tangerine peel. Fresh tangerine peel tastes good, so it is better to use old one if possible, so the old tangerine peel is called dermis (陳皮). The dermis is rich in vitamin C, citric acid and hesperidine, a vitamin P that is capillary potentiating. Limonene accounts for over 90% of essential oils and contains a large amount of flavonoids such as serotonin and hesperidine. The main pharmacological action of the dermis is secretion of exocrine gland by nose olfactory reflection, increase of lipase activity, anti-allergic effect, suppression of contraction of uterine muscle, sedative effect, inhibition of capillary and permeability and capillary strengthening Hardening and hypertension prevention effect. The nature of the dermis is warm and nontoxic, the taste is hot and bitter. In Chinese medicine, the dermis is mainly used as goyang placebo, antitussive expectorant, and antiperspirant.

The fruit (Poncirus trifoliata Rafinesque) is called raw fruit and contains isosakuranin, naringin, citriforlioside and poncirin in the flowers, limonene in the flowers, and skimmianine in the leaves. Medicinal benefits include food discord, stomach and sewage, mudfish, chest obesity cramps, expectoration, news, small intestine, This is a medicinal herb that is a directional high-density placebo. It is used for gastric ulcer, gastrointestinal dyspepsia, allergic constitution, gastric gas removal, uterine sewage and visceral dysfunction.

Euphoria longana is good for symptoms such as insomnia caused by nerve hypersensitivity or overwork, insomnia and other conditions.It is also good for the treatment of forgetfulness and phobia and for wisdom.27% of vitamina, b1, Tartaric acid, glucose, organic sugar, organic acid , Saponin, etc., and jujube (Sanjoin) is similar to sedative antifungal and pharmacological action to inhibit S. germ, tonic action, antioxidant action, immune function activation action, digestive diseases, gynecological It is said to be effective in removing coronary artery disease and coronary artery disease and dysentery.

Nyphaea nelumbo L. is a perennial herbaceous plant with thick and short roots but with a large number of beard roots. The composition is composed of Ellagic acid, Gossypitrin, Nymphaeine and flowers are used as hemostasis and tonic. It has weak sexual function, and there are oil wells and dreams, as well as your wife's white malaise and nerves are sensitive, so your heart beats, surprises and can't sleep, and your digestive function is weak. It stabilizes and helps kidney function and is also good for women and is being used in various ways as food raw materials and herbal teas.

Keel (Fossilia Ossis Mastodi) is a fossil of skeletons of large vertebrates. It is mainly calcium-containing, hard-relief, fixed, and has an anti-inflammatory effect.

Aucklandia lappa Dene cools the essential oil (1-5%) in the roots and rhizomes to obtain crystals, called helenin. And inulin, pseudo inulin, saponins, bitter substances, etc. Others include Scoplatin and Umbeliferon. Good for chest pain, dysentery, vomiting, and the root decoction has a strong effect of letting out phlegm. It also inhibits anti-inflammatory, increased intestinal motility and secretion. Essential oils have antiseptic and anti-inflammatory properties. It is used for various respiratory diseases including bronchitis and pulmonary tuberculosis.

      Gardenia (Gardenia jasminoides for.grandiflora) is called fruit gardenia, and oriental medicine is used to treat insomnia and jaundice and has anti-inflammatory, hemostatic and diuretic effects. It is used as a colorant for food, and in the old days, it was stored in gardenia water and steamed to prevent the deterioration of military taste.

Because of the many therapeutic results based on natural medicines based on the East and West, the present inventors have developed drugs useful for the treatment of symptoms caused by hypertension, hypertension, stroke, myocardial infarction, angina pectoris and thrombus in the medicines derived from herbal medicines. .

The present invention includes Poria cocas Wolf, Cyperus rotundu, Pinellia ternata Tenore et Breit., Dermis (Citrus nobilis), Euphoria longana, Nyphaea nelumbo L., Auklandia lappa Dene), the pharmaceutical composition for the treatment of symptoms caused by hypertension, hypertension, stroke, myocardial infarction, angina pectoris and thrombus containing as the main ingredient Gardenia jasminoides for grandiflora, or X as its main ingredient and extracted with a selected solvent The added compositions provide surprising results in the suppression of symptoms caused by hypertension, hypertension, stroke, myocardial infarction, angina pectoris and thrombus in molecular biological and animal experiments.

Another object of the present invention is Poria cocas Wolf, Cyperus rotundu, Pinellia ternata Tenore et Breit., Citrus nobilis, Euphoria longana, Nyphaea nelumbo L. (Aucklandia lappa Dene), Gardenia jasminoides for.grandiflora, the main component of the treatment of symptoms of hypertension, hypertension, stroke, myocardial infarction, angina and thrombus or its extract as a main component and selected solvent It is to provide the extracted X addition.

Each herbal ingredient may be powdered, or each may be extracted alone to obtain an extract, and these extracts may be mixed or the necessary herbal ingredients may be combined and extracted together.

Extraction can be performed by heating to the boiling point temperature of the solvent used.

Heating time is performed for 1 to 12 hours preferably 2 to 6 hours.

Next, the present invention will be described in more detail with reference to Examples and Experimental Examples, which do not limit the scope of the present invention. It does not limit the scope of the invention.

Example 1

1.Weigh the total dry weight of herbal medicine such as 1,000 g, and mix it with volume of 10 times with tertiary distilled water (or purified water), and gradually heat it for 6 hours under 80 ℃ condition to make the final volume 2,000 ml. Then, it was concentrated under reduced pressure and freeze-dried to obtain a freeze-dried weight of 250g (hereinafter referred to as vitality) (Fig. 1).

2. A composition that is extracted and separated from the water extract. In the present invention, 1,000 g of dry weight in each of the extraction methods was mixed in 10,000 ml of distilled water, and the resulting filtrate was filtered and extracted by filtering with gauze for 12 hours in a water bath at 80 ° C. in a boiling water bath for 6 hours under reflux. Extracted once more. It was concentrated under reduced pressure again and lyophilized to obtain a dry weight of about 250 g. It is another object of the present invention to provide a process for separating and purifying water extracts X.

Water extract obtained in the series of drying as described above is effective in the composition of the present invention because it has a therapeutic effect of cardiovascular diseases such as hypertension, hyperlipidemia, stroke, myocardial infarction, arteriosclerosis, angina as described below Can be used as a component.

Example 2

Poria cocas Wolf, Cyperus rotundu, Pinellia ternata Tenore et Breit., Dermis (Citrus nobilis), Euphoria longana, Nyphaea nelumbo L., Akklandia lappa Dene, The pharmaceutical composition of the treatment of cardiovascular diseases such as hypertension, hyperlipidemia, stroke, myocardial infarction, arteriosclerosis, angina pectoris containing Gardenia jasminoides for grandiflora as a main ingredient is extracted with water in the same manner as in Example 1 to obtain X.

Example 3

1-10% by weight of Poria cocas Wolf, 1-10% by weight of Cyperus rotundu, 1-10% by weight of Pinellia ternata Tenore et Breit., 1-10% by weight of the dermis (Citrus nobilis) By weight, Euphoria longana 1 to 10% by weight, 1 to 10% by weight of Nyphaea nelumbo L., 1 to 10% by weight of Mokyang (Aucklandia lappa Dene), Gardenia jasminoides for grandiflora Pharmaceutical composition for the treatment of cardiovascular diseases such as hypertension, hyperlipidemia, stroke, myocardial infarction, arteriosclerosis and angina containing 1 to 10% by weight as a main component, and extracted with water as in Example 2 to obtain a powder.

Experimental Example 1 Heart rate measurement and vasoconstriction test

Six rats in each group were treated with normal and non-selective NOS inhibitor N-nitro-L-arginine methyl ester (NAME: 50 mg / KG) daily. The cardiac aorta was cut out from the rats of the day 1 and submerged in a cooled Krebs solution (119 mM NaCl, 4.6 mM KCl, 15 mM Na₂CO₃, 1.5 mM CaCl₂, 1.2 mM MgCl₂, 1.2 mM NaH₂PO₄, 11 mM glucose) After careful removal, it was cut to a length of 5m ㅣ. The aortic sections were suspended in 5ml double bottles at 37 ° C and 95% O₂-5% CO₂ was supplied continuously to the Krebs solution. The contractile force of blood vessels was recorded in a physiograph connected to a force transducer. Change the tension several times until the vessel's rest tension is maintained at 1.5 g, and then change it to a new Krebs solution every 15 minutes, stabilize the vessel for more than 90 minutes, and then use the Krebs solution containing 25 mM KCl for maximum contraction force. After the blood vessels were washed and the blood vessels were stabilized again for at least 30 minutes, the contraction of the drug to be tested was measured. The normal group was 1.3 ± 0.2 g, the L-NAME group was 2.1 ± 0.5 g and the vital group was 1.4 ±. Shrinkage of 0.3 g occurred and was significantly reduced, particularly in the vital group (FIG. 2).

Experimental Example 2 Measurement of Platelet Plasma Cohesion and Thrombosis Formation Ability

Using anti-coagulation from blood, 0.38% sodium citrate and 1% glucose were used to precipitate and remove non-platelet cells such as leukocytes and erythrocytes using a centrifuge, and most of the platelets remained in the supernatant plasma. In order to prepare rich plasma, supernatant platelet plasma (PRP) was prepared by centrifugation at 200 xg for 10 minutes, followed by 10 mM HEPES buffer (pH7.4: 140 mM NaCl, 5 mM NaHCO3, 0,5 mM MgCl2, 3 mM KCl, 140 mM). Into a platelet plasma containing glucose), 20 μl of the test sample solution was added and cultured for 2 minutes at 37 ° C., and platelets washed by adding 20 μl of collagen (C) to thrombin (T), which are inducers of platelet aggregation, were washed in a plasma tube. Resuspended and reacted with 10 nM thrombin or collagen (100 ㎍ / ml) containing 2 mM calcium to treat the drug and keep the reaction at room temperature for 30 minutes to induce thrombosis. On the other hand it does not appear the control group (T + C) is decreased when energy production, but thrombus is induced strongly (Fig. 3).

Experimental Example 3 ECV304 Vascular Endothelial Cell Survival Rate

The cell line ECV304 used in this experiment is a 10 ³ cells were cultured on a dish for flask to cell culture by the addition of penicillin / streptomycin in DMEM medium containing 5% FBS by subculture receive pre-sale from excessive regular beam professor of Chungbuk 6 Dispense in a well-well plate, incubate overnight at 37 ° C, incubate at 80% density, wash twice with serum free medium, add 1 ml SFM, and react with 10 nM thrombin or collagen (100 ㎍ / ml). Induced vascular damage of the cardiovascular system by treatment in order to investigate the cell survival rate, divided into the control group, the control group treated with agonist, and the experimental group treated with agonist and vitality, incubated for 12 hours at 37 ℃ and then 100 μl of each group Was transferred to a 96-well plate and 20 μl of pyruvate substrate (NADH 1mg / ml) was added thereto, followed by mixing at room temperature for 2 minutes and shaking at 37 ° C. for 30 minutes. After 20 μl of color reagent (Sigma 505-2) was added and mixed for 20 minutes at room temperature, 100 μl of 0.4N NaOH was added and mixed for 15 minutes at room temperature, and then absorbance was measured by ELISA reader. All experiments were performed at least three times, and the control group was expressed as a percentage (% Control). The statistical significance was indicated as P <0.05 by t-test, and as a result, the normal group of vascular endothelial cells and platelet activity inducer. Necrosis induced by necrosis by collagen and thrombin 20μl in the necrosis inhibiting ability of the group to which vigor was added, the normal group induced the necrosis of endothelial cells within 100%, but in the vigorous case, the degree of necrosis was inhibited by 50%. IC ₅₀ was about 25 [mu] g / ml and the necrosis of endothelial cells was inhibited by the activation of apoptosis by the addition of two inducers (Fig. 4).

Experimental Example 4 Tunel assay of ECV304 vascular endothelial cells

To investigate the effect of thrombin, agonist on cardiovascular injury by inducing cardiovascular damage through ECV304, vascular endothelial cells, the control group was treated with agonist-treated control group and agonist and vigor-treated experimental group. After incubation for 4 hours, the cells were dispensed on a cover glass, incubated overnight, and the drug concentration was added to a concentration of 25 ㎍ / ml. After 6 hours, Tunel assay was performed to investigate whether cell death was inhibited. After removing the medium and washing with PBS, the cells were fixed at 4 for 4 hours with 4% p-formaldehyde, and then infiltrated at room temperature for 15 minutes by adding 0.5% Tween 20 and 0.2% BSA (bovine serum albumin). Wash 3 times with PBS and drop 5 µl of terminal deoxynucleotidyl transferase (TdT) solution (TdT buffer, biotin-dUTP, TdT = 18: 1: 1) to label intracellular chromosomal DNA nick ends. Maintain time and wash 3 times with distilled water, add 50μl of 0.5% BSA blocking solution, leave at room temperature for 10 minutes, add 50μl of streptoavidine-FITC solution, keep at room temperature for 30 minutes and wash 3 times with PBS. Next, drop the mounding solution on the slide glass, place it upside down, and observe it under the fluorescence microscope to determine the presence of green fluorescence staining. The cell death was confirmed by necrosis by the normal group, collagen and thrombin. Investigation of the nucleus of the treated control group and the treated group treated with 25 ㎍ / ml induced the cell nucleus cleavage by the control group showing a strong green fluorescence while the control group showed a strong green fluorescence. The green fluorescence signal showed a tendency to decrease (FIG. 5).

Experimental Example 5 Tissue Analysis of Heart Cells

To confirm the presence of necrosis or tissue necrosis of arterial endothelial cells in the periphery of the rat heart, oral administration of the control group and vitals administered subcutaneously with NAME (50 mg / KG) for 2 weeks. In one group, rats were anesthetized with ketamin, and then dissected and paraffin embedded around the coronary artery to perform immunohistochemical staining. After oral administration of the drug for 2 weeks, strangulation was performed to fix the cardiac tissue area with formalin, cut into microtome with a thickness of 5 μm, and serial sections were reacted for 20 minutes in 2N HCl solution to perform DNA-denaturation and 0.1M borate buffer treatment. After stabilizing the cells, 0.5% bovine serum albumin containing 0.01% proteinase K (DAKO, Denmark) was reacted for 1 hour to suppress nonspecific immune responses. The next primary antibody, iNOS and CPP, were reacted for 12 hours in a 4 ° C. cold room. Horseradish peroxidase-antibody-labeled avidin biotin complex (ABC: Vector Lab, USA) reacted at room temperature for 1 hour at 0.05M Tris- containing 0.05% 3,3-diaminobenzidine (DAB: Sigma) and 0.01% HCl. After staining with HCl buffer (pH 7.4), H / E staining was observed under the optical microscope under 100X microscope. The periarterial artery was well developed around the coronary artery, but the L-NAME treatment group lost or destroyed due to necrosis. In particular, unlike the control group in which the thickness of peripheral vascular endothelial cells was reduced, the drug treatment group showed similar results to the normal group due to the induction of cell proliferation. In addition, when the degree of vascular periphery was observed, the control group caused the destruction of blood vessels due to necrosis, but the vitality of the endothelial cells was maintained uniformly, similar to the normal group. On the other hand, iNOS showed a strong brown reaction in the periphery of the control arteries as shown in FIG. 6, indicating that the cell necrosis was strongly induced, and that the control showed a strong brown reaction at the periphery of the blood vessels. In contrast, the livestock tended to be weakly expressed. These results suggest that CPP3 induces the expression of perivascular disruption at the same time. Endothelial cell death by L-NAME is induced by NO-induced NO death by iNOS, leading to cell death and necrosis. The hypothesis that myocardial infarction or cardiac arrest may occur is thought to contain a component that inhibits vitality.

As confirmed from the above experimental results, the active pharmaceutical composition of the present invention has excellent pharmacological effects of treating hypertension, hypertension, stroke, myocardial infarction, angina pectoris and thrombosis. Therefore, the present invention can be usefully used as a pharmaceutical effect in the treatment of symptoms caused by cardiovascular diseases hypertension, hypertension, stroke, myocardial infarction, angina pectoris and thrombus. The amount of the drug may vary depending on the sex, age, and severity of the patient due to the pharmacological effects of the present invention. However, when the herbal medicine itself is used without extracting the composition of the present invention with water or an organic solvent, the amount of the drug may be 1.0 g per day. An amount of 50 g may be used, and when used in the form of X, 10 mg to 1000 mg per day may be administered once to several times per day.

The compound of the present invention further contains at least one drug selected from calcium antagonists and renin inhibitors, which are already used as drugs, having an effect on symptoms caused by cardiovascular diseases such as hypertension, hypertension, stroke, myocardial infarction, angina pectoris and thrombus. It may also be used in combination with drugs such as excipients, adjuvants, diluents, isotonic agents, preservatives, suspending agents, solubilizing agents, and the like, which are pharmaceutically conventionally acceptable thereto.

By using the compound of the present invention and the above drug, it is possible to reduce the normal dose of the existing drug, thereby reducing the problems with the existing drugs.

The compounds of the present invention are mixed with excipients, adjuvants, analgesics, isotonic agents, preservatives and other pharmaceutically acceptable adjuvants used in the pharmaceutical industry, and formulated in the form of pharmaceutically acceptable formulations for pharmaceutical preparation. Formulations may be prepared. Such pharmaceutical preparations may be formulated into injections, solutions, tablets, capsules, powders, syrups and the like.

Next, the present invention will be described in more detail as formulation examples.

Formulation Example 1

500 mg of water extract powder of Example 1

Lactose 100mg

Starch 100mg

Terpenadine

The above components are mixed and tableted according to a conventional method for producing tablets to produce tablets.

Formulation Example 2

Water extract powder 500m of Example 1

Lactose 100mg

Starch 50mg

Cetirizine appropriate amount

The above components are mixed and tableted according to a conventional method for producing tablets to produce tablets.

Formulation Example 3

500 mg of water extract powder of Example 1

Lactose 100mg

Zirtec 2 mg

After mixing the above components, the inside is filled with a polyethylene coated coated chloride and sealed to prepare a powder.

Formulation Example 4

X 500mg of Example 1

As described in detail above, Poria cocas Wolf, Cyperus rotundu, Pinellia ternata Tenore et Breit., Dermis (Citrus nobilis), Euphoria longana, Nyphaea nelumbo L., Mokhyang (Aucklandia lappa Dene), a pharmaceutical composition for treating symptomatic diseases caused by hypertension, hypertension, stroke, myocardial infarction, angina pectoris and blood clots, which are cardiovascular diseases, which contains Gardenia lapoide (Gardenia jasminoides for grandiflora) as a main ingredient. The composition containing the extracted X as a main component has excellent pharmaceutical effects on the symptoms of cardiovascular diseases such as hypertension, hypertension, stroke, myocardial infarction, angina pectoris and blood clots.

Figure 1 shows a method for recovering the dry weight according to the extraction process of the active compound as a pharmaceutical composition.

Figure 2 shows the vitality of the heart contractility relief.

Figure 3 shows the vitality of the platelet aggregation inhibitory effect.

Figure 4 shows the vitality of the vascular endothelial necrosis inhibition

Figure 5 shows the cell death inhibitory effect confirmed by the tunel assay

Figure 6 shows the protein expression related to heart tissue necrosis

Claims (2)

1-10% by weight of Poria cocas Wolf, 1-10% by weight of Cyperus rotundu, 1-10% by weight of Pinellia ternata Tenore et Breit., 1-10% by weight of the dermis (Citrus nobilis) Parts by weight, 1 to 10% by weight of Euphoria longana, 1 to 10% by weight of Nyphaea nelumbo L., 1 to 10% by weight of Aurlandia lappa Dene, Gardenia (Gardenia jasminoides for. Grandiflora) A pharmaceutical composition excellent in the treatment of symptoms caused by hypertension, hypertension, stroke, myocardial infarction, angina and thrombus, which is a cardiovascular disease containing x extracted with a solvent selected from powder or water at 1 to 10% by weight. 1-10% by weight of Poria cocas Wolf, 1-10% by weight of Cyperus rotundu, 1-10% by weight of Pinellia ternata Tenore et Breit., 1-10% by weight of the dermis (Citrus nobilis) Parts by weight, 1 to 10% by weight of Euphoria longana, 1 to 10% by weight of Nyphaea nelumbo L., 1 to 10% by weight of Aurlandia lappa Dene, Gardenia (Gardenia jasminoides for. Grandiflora) Excellent pharmaceutical efficacy in the treatment of symptoms caused by hypertension, hypertension, stroke, myocardial infarction, angina pectoris and thrombus, which is a cardiovascular disease containing X extracted with 1 to 10% by weight or a solvent selected from water thereof